MedTrace Logo

Embosphere® PROstate Post Market Study

NCT03527589 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 499

Last updated 2023-12-18

Study results available
· View outcomes & findings →

Summary

Prostatic artery embolization with Embosphere Microspheres is a relatively new procedure. The goal of this post market study is to evaluate long-term safety and effectiveness in a 'real world' setting.

Conditions

  • Benign Prostatic Hyperplasia
  • Lower Urinary Tract Symptoms

Interventions

DEVICE

Prostate artery embolization

Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.

Sponsors & Collaborators

  • Merit Medical Systems, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-16
Primary Completion
2020-01-21
Completion
2022-01-22
FDA Device
Yes

Countries

  • United States
  • France
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03527589 on ClinicalTrials.gov